Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2022-10-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于对下属公司担保的进展公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the progress of guarantees provided by the company to its subsidiaries. It includes specifics about guarantee contracts, amounts, terms, and the board's opinion on the guarantees. It is not a financial report like an annual or interim report, nor is it a certification or voting result. It is a regulatory announcement about financing guarantees and related risk disclosures. The document length is 4273 characters, which is relatively short but contains substantive content about guarantees rather than just announcing a report publication. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-10-11 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, prices, compliance with regulatory rules, and future plans for repurchase. It does not contain financial statements or comprehensive financial data but focuses on the share buyback activity. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2022-10-10 Chinese
关于股东权益变动的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement by 普洛药业股份有限公司 regarding a change in shareholder equity due to a merger between two shareholders, 浙江埃森化学有限公司 and 横店集团康裕药业有限公司. It details the shareholding percentages before and after the merger, the companies involved, and confirms that the controlling shareholder and actual controller remain unchanged. The document is a notification about changes in major shareholding and related corporate actions, not a full financial report or earnings release. It fits the definition of a Major Shareholding Notification (MRQ) as it informs about changes in significant share ownership levels and control structure.
2022-09-30 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 普洛药业股份有限公司 regarding the receipt of a drug registration certificate for a pharmaceutical product by its subsidiary. It details the drug's specifications, approval, market data, and potential impact on the company. There is no financial data, no mention of financial results, no regulatory filings related to financial performance, no management or board changes, no voting results, no merger or acquisition activity, and no report publication. The document is an official announcement about a regulatory approval related to the company's product, which fits best under general regulatory announcements. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short and it is not a report itself but an announcement, so it is not a full report type like 10-K or IR.
2022-09-20 Chinese
关于股东股份解除质押的公告
Transaction in Own Shares Classification · 95% confidence The document is a short announcement regarding the release of pledged shares by a shareholder. It includes details about the shareholder, the number of shares released from pledge, and related information. There is no financial report, earnings data, or management discussion. The document is an official notice about a change in share pledge status, which fits the category of Transaction in Own Shares (POS) as it relates to shareholding changes and capital structure implications. The document length is short and focused on this specific event, not a full report or announcement of a report publication.
2022-09-07 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 普洛药业股份有限公司 regarding the receipt of a drug registration certificate for a specific pharmaceutical product. It details the drug's specifications, approval, and potential impact on the company. The document is short (1072 characters) and serves as an official announcement rather than a detailed report or financial statement. It does not contain financial data, management discussion, or regulatory certifications. It is not related to annual reports, earnings, board changes, or other specific filings. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous official announcements that do not fit other categories.
2022-09-05 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.